Beer sales and events will benefit ALS research at the ALS Therapy Development Institute
Revival Brewing, along with over 145 breweries from 39 states across the United States are participating in Ales for ALS™ this summer, a charitable program that raises money for the ALS Therapy Development Institute (ALS TDI) in Cambridge, MA. Ales for ALS breweries raise money through sales of their unique, limited-edition Ales for ALS beers made from a blend of experimental hops donated by B.T. Loftus Ranches and YCH Hops and through proceeds generated from events and festivals. Since 2013, Ales for ALS breweries have raised over $1,750,000 for ALS research taking place at ALS TDI.
“The breweries participating in Ales for ALS and the people who come to sample the beers are funding the necessary scientific efforts and providing real impact on the research here at the ALS Therapy Development Institute,” says Steve Perrin, Ph.D., CEO and CSO of ALS TDI.
The Revival Brewing Ales for ALS beer is now available on draft in their Tasting Room located downstairs at 505 Atwood Avenue in Cranston, RI. It’s a Golden Ale at 5% ABV and 15 IBUs that’s super refreshing with a crisp, lightly toasted malt character.
For more information about Ales for ALS, participating breweries, festivals and events, please visit www.alesforals.com. For regular updates about the program, including select brewery “takeovers” on Instagram, follow Ales for ALS on Facebook and Instagram.
About the ALS Therapy Development Institute
The ALS Therapy Development Institute and its scientists actively discover and develop treatments for ALS. It is the world’s first and largest nonprofit biotech focused 100 percent on ALS research. Led by people with ALS and drug development experts, it understands the urgent need to slow and stop this disease. As the world’s foremost drug discovery center focused solely on ALS, ALS TDI spends 87% of every dollar raised on research to find effective treatments and cures. Its innovative science and cutting edge approach have resulted in the identification of AT-1501, a promising treatment for ALS. It also pioneered the ALS Precision Medicine Program, the world’s premier program and partnership with ALS patients to discover additional potential treatments. For more information, visit www.als.net.